Author (year) | Patients | Weeks | Drug, dose | Outcomes | |||||||
Global/ composite | Dryness | Pain | Fatigue | HRQoL | Salivary flows | Ocular tests | ESSDAI | ||||
Mariette et al12 (2004) | 103 | 22 | Infliximab, 5 mg/kg | VAS | VAS | VAS | VAS | SFR | Schir | ||
Sankar et al (2004)67 | 28 | 12 | Etanercept, 25 mg | VAS | VAS | SFR | Liss, Schir | ||||
Dass et al13 (2008) | 17 | 24 | RTX, 1 g/15 days | VAS | SF-36* | ||||||
Meijer et al10 (2010) | 30 | 48 | RTX, 1 g/15 days | VAS* | MFI | SF-36 | SWS | Liss, BUT, Schir | |||
Norheim et al14 (2012) | 26 | 4 | Anakinra, 100 mg/day | VAS | BDI | ||||||
Devauchelle-Pensec et al15 (2014) | 122 | 24 | RTX, 1 g/15 days | VAS | VAS | VAS | VAS | SF-36 | SFR | Schir | Mean improvement |
Bowman et al19 (2017) | 133 | 48 | RTX, 1 g/15 dys | VAS | VAS oral | VAS | ESSPRI, SF-36 | UWS* | Lachr flow | Log-transf | |
St Clair et al18 (2018) | 52 | 24 | Baminercept, 100 mg weekly | VAS | VAS | VAS | UWS, SWS | Liss, Schir* | Mean score |
Grey cells=primary outcome.
*Statistically significant.
BDI, Beck Depression Inventory; ESSDAI, EULAR Sjögren's syndrome disease activity index; ESSPRI, EULAR Sjogren's Syndrome Patient Reported Index; HRQoL, health-related quality of life; MFI, Multidimensional Fatigue Inventory; RCT, randomised controlled trial; RTX, rituximab; Schir, schirmer; SF-36, Short Form-36 Health Survey; SFR, salivary flow rate; SFR, salivary flow rate; UWS, unstimulated whole saliva; VAS, visual analogue scale.